Injectafer FDA Approval History
FDA Approved: Yes (First approved July 25, 2013)
Brand name: Injectafer
Generic name: ferric carboxymaltose
Dosage form: Injection
Company: Daiichi Sankyo Inc.
Treatment for: Iron Deficiency Anemia
Injectafer (ferric carboxymaltose) is an iron replacement product for the treatment of iron deficiency anemia.
- Injectafer is indicated:
- for the treatment of iron deficiency anemia (IDA) in adults and pediatric patients 1 year of age and older who have either intolerance to oral iron or an unsatisfactory response to oral iron, and adult patients who have non-dialysis dependent chronic kidney disease
- to improve exercise capacity in people with iron deficiency anemia and New York Heart Association (NYHA) class II/III heart failure.
Development timeline for Injectafer
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.